Protara Therapeutics (TARA) Accumulated Expenses (2013 - 2026)
Protara Therapeutics (TARA) posted quarterly Accumulated Expenses of $3.6 million for Q1 2026, up 37.8% year-over-year from $2.6 million in Q1 2025, and up 35.18% quarter-over-quarter from $2.7 million in Q4 2025.
Protara Therapeutics (TARA) Accumulated Expenses (2013 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Accumulated Expenses for 14 consecutive years, with $3.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses rose 37.8% year-over-year to $3.6 million; the TTM figure through Mar 2026 stood at $3.6 million (up 37.8% YoY), while the FY2025 annual figure was $2.7 million, down 2.08% from the prior year.
- Accumulated Expenses grew to $3.6 million in Q1 2026 per TARA's latest filing, from $2.7 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $3.6 million in Q1 2026 and bottomed at $440000.0 in Q4 2023.
- Historically, Accumulated Expenses has averaged $2.3 million across 5 years, with a median of $2.4 million in 2022.
- Annual changes were most pronounced in 2022 — Accumulated Expenses surged 2688.46% — and 2023, when it plunged 86.41%.
- Protara Therapeutics' Accumulated Expenses stood at $3.2 million in 2022, then slumped by 86.41% to $440000.0 in 2023, then jumped by 522.73% to $2.7 million in 2024, then dropped by 2.08% to $2.7 million in 2025, then soared by 35.18% to $3.6 million in 2026.
- Business Quant data shows TARA's Accumulated Expenses at $3.6 million in Q1 2026, $2.7 million in Q4 2025, and $2.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.37 Mn |
| Mar 31, 2026 | 3.63 Mn |
| Dec 31, 2025 | 2.68 Mn |
| Sep 30, 2025 | 2.24 Mn |
| Jun 30, 2025 | 1.45 Mn |
| Mar 31, 2025 | 2.63 Mn |
| Dec 31, 2024 | 2.74 Mn |
| Sep 30, 2024 | 3.39 Mn |
| Jun 30, 2024 | 2.11 Mn |
| Mar 31, 2024 | 3.53 Mn |
| Dec 31, 2023 | 440,000.00 |
| Sep 30, 2023 | 3.31 Mn |
| Jun 30, 2023 | 936,000.00 |
| Mar 31, 2023 | 1.40 Mn |
| Dec 31, 2022 | 3.24 Mn |
| Sep 30, 2022 | 2.35 Mn |
| Jun 30, 2022 | 2.22 Mn |
| Mar 31, 2022 | 1.45 Mn |
| Dec 31, 2021 | 2.49 Mn |
| Sep 30, 2021 | 142,000.00 |